高级检索

疑似膀胱肿瘤的血尿患者中荧光原位杂交技术的应用

王业华, 顾沈阳, 刘亚东, 杜拥军

王业华, 顾沈阳, 刘亚东, 杜拥军. 疑似膀胱肿瘤的血尿患者中荧光原位杂交技术的应用[J]. 实用临床医药杂志, 2012, (19): 26-28.
引用本文: 王业华, 顾沈阳, 刘亚东, 杜拥军. 疑似膀胱肿瘤的血尿患者中荧光原位杂交技术的应用[J]. 实用临床医药杂志, 2012, (19): 26-28.
shu
WANG Yehua, GU Shenyang, LIU Yadong, DU Yongjun. Application of fluorescent in situ hybridization in suspected bladder cancer with hematuresis[J]. Journal of Clinical Medicine in Practice, 2012, (19): 26-28.
Citation: WANG Yehua, GU Shenyang, LIU Yadong, DU Yongjun. Application of fluorescent in situ hybridization in suspected bladder cancer with hematuresis[J]. Journal of Clinical Medicine in Practice, 2012, (19): 26-28.
shu

疑似膀胱肿瘤的血尿患者中荧光原位杂交技术的应用

  • 扬州大学临床医学院泌尿外科,江苏扬州,225001

详细信息

  • 中图分类号: R737.14

Application of fluorescent in situ hybridization in suspected bladder cancer with hematuresis

摘要

    摘要
  • 摘要: 目的 利用荧光原位杂交技术(FISH)检测尿脱落细胞中阳性细胞百分率的不同,探讨其在膀胱肿瘤诊断中的意义.方法 因血尿怀疑膀胱肿瘤的患者40例,留取患者的尿液做FISH检测,根据FISH结果阳性细胞百分率不同分成4组,分别是0％ ～5％、6％～10％、11％～20％、≥21％.结果 FISH阳性细胞百分率为0％ ～5％、6％～10％、11％～20％、≥21％4组诊断膀胱肿瘤的准确率分别是55.6％、71.4％、92.3％、100％.高级别膀胱肿瘤与低级别膀胱肿瘤阳性细胞百分率差异具有统计学意义(P＜0.05).Ta、T1、T2期膀胱肿瘤阻性细胞百分率差异无统计学意义.结论 膀胱肿瘤的发生与FISH阳性细胞百分率具有正相关性,阳性细胞百分率越高膀胱肿瘤发生率越高.
    • HTML全文
    • 参考文献(11)
  • Jemal A, Siegel R, Xu J. Cancer statistics, 2010 [J]. CA:A Cancer Journal for Clinicians, 2010.277.
    Tissot W D, Diokno A C, Peters K M. A referral center's experience with transitional cell carcinoma misdiagnosed as interstitial cystitis [J]. The Journal of Urology, 2004(2):478.
    Chang S S, Hassan J M, Cookson M S. Delaying radical cystectomy for muscle invasive bladder cancer results in worse pathological stage [J]. The Journal of Urology, 2003, (4 Pt 1):1085.
    Sánchez-Ortiz R F, Huang W C, Mick R. An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma [J]. The Journal of Urology, 2003(1):110.
    Yoder B J, Skacel M, Hedgepeth R. Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology:a prospective study with focus on the natural history of anticipatory positive findings [J]. American Journal of Clinical Pathology, 2007(2):295.
    Varella Garcia M, Akduman B, Sunpaweravong P. The UroVysion fluorescence in situ hybridization assay is an effective tool for monitoring recurrence of bladder cancer [J]. Urologic Oncology, 2004(1):16.
    Kipp B R, Tanasescu M, Else T A. Quantitative Fluorescence in Situ Hybridization and its Ability to Predict Bladder Cancer Recurrence and Progression to Muscle-Invasive Bladder Cancer [J]. Journal of Molecular Diagnostics, 2009(2):148.
    Sarosdy M F, Kahn P R, Ziffer M D. Use of a Multitarget Fluorescence In Situ Hybridization Assay to Diagnose Bladder Cancer in Patients With Hematuria [J]. The Journal of Urology, 2006(1):44.
    Shariat S F, Marberger M J, Lotan Y. Variability in the performancc of nuclear matrix protein 22 for the detection of bladder cancer [J]. The Journal of Urology, 2006(3):919.
    Liedberg F, Anderson H, Mansson A. Diagnostic delay and prognosis in invasive bladder cancer [J]. Scandinavian Journal of Urology and Nephrology, 2003(5):396.
    Wallace D M, Bryan R T, Dunn J A. Delay and survival in bladder cancer [J]. British Journal of Urology International, 2002.868.
    • 相关文章
    • 施引文献
    • 资源附件(0)
计量
  • 文章访问数: 
  • HTML全文浏览量: 
  • PDF下载量: 
  • 被引次数: 0
出版历程
  • 发布日期:  2013-01-15

目录

摘要
HTML全文
    参考文献(11)
    相关文章
    施引文献
    资源附件(0)

    /

    返回文章
    返回

    © 2020 《实用临床医药杂志》编辑部

    地址：江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室邮编：225009电话：0514-87978917、87978989、87978807

    苏公网安备 32100302010246号

    本系统由 北京仁和汇智信息技术有限公司 开发  百度统计